MedTrace Logo

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

NCT04109456 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-01-15

No results posted yet for this study

Summary

This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in subjects with metastatic uveal melanoma and NRAS-mutant metastatic melanoma.

Conditions

Interventions

DRUG

IN10018

100 mg or 50mg, orally once daily continuously;

DRUG

Cobimetinib

60mg , orally once daily from day 1 to day 21 in a 28-day cycle

BIOLOGICAL

Atezolizumab

biweekly 840 mg dose will be used in this study starting from Cycle 2.

Sponsors & Collaborators

  • InxMed (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Eddie Xing, Dr. · InxMed Shanghai

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-16
Primary Completion
2024-12-20
Completion
2024-12-20
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04109456 on ClinicalTrials.gov